270 related articles for article (PubMed ID: 30606612)
21. Characterization of CD34+ hematopoietic progenitor cells in JAK2V617F and CALR-mutated myeloproliferative neoplasms.
Angona A; Alvarez-Larrán A; Bellosillo B; Longarón R; Camacho L; Fernández-Rodríguez MC; Pairet S; Besses C
Leuk Res; 2016 Sep; 48():11-5. PubMed ID: 27427771
[TBL] [Abstract][Full Text] [Related]
22. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.
Nangalia J; Massie CE; Baxter EJ; Nice FL; Gundem G; Wedge DC; Avezov E; Li J; Kollmann K; Kent DG; Aziz A; Godfrey AL; Hinton J; Martincorena I; Van Loo P; Jones AV; Guglielmelli P; Tarpey P; Harding HP; Fitzpatrick JD; Goudie CT; Ortmann CA; Loughran SJ; Raine K; Jones DR; Butler AP; Teague JW; O'Meara S; McLaren S; Bianchi M; Silber Y; Dimitropoulou D; Bloxham D; Mudie L; Maddison M; Robinson B; Keohane C; Maclean C; Hill K; Orchard K; Tauro S; Du MQ; Greaves M; Bowen D; Huntly BJP; Harrison CN; Cross NCP; Ron D; Vannucchi AM; Papaemmanuil E; Campbell PJ; Green AR
N Engl J Med; 2013 Dec; 369(25):2391-2405. PubMed ID: 24325359
[TBL] [Abstract][Full Text] [Related]
23. Frequency of Calreticulin (CALR) Mutation and Its Clinical Prognostic Significance in Essential Thrombocythemia and Primary Myelofibrosis: A Meta-analysis.
Kong H; Liu Y; Luo S; Li Q; Wang Q
Intern Med; 2016; 55(15):1977-84. PubMed ID: 27477402
[TBL] [Abstract][Full Text] [Related]
24. Calreticulin exon 9 mutations in myeloproliferative neoplasms.
Ha JS; Kim YK
Ann Lab Med; 2015 Jan; 35(1):22-7. PubMed ID: 25553276
[TBL] [Abstract][Full Text] [Related]
25. Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations.
Andrikovics H; Krahling T; Balassa K; Halm G; Bors A; Koszarska M; Batai A; Dolgos J; Csomor J; Egyed M; Sipos A; Remenyi P; Tordai A; Masszi T
Haematologica; 2014 Jul; 99(7):1184-90. PubMed ID: 24895336
[TBL] [Abstract][Full Text] [Related]
26. CALR mutation characterization in myeloproliferative neoplasms.
Bilbao-Sieyro C; Florido Y; Gómez-Casares MT
Oncotarget; 2016 Aug; 7(33):52614-52617. PubMed ID: 27384487
[TBL] [Abstract][Full Text] [Related]
27. Calreticulin Immunohistochemistry in Myeloproliferative Neoplasms - Evolution of a New Cost-Effective Diagnostic Tool: A Retrospective Study with Histological and Molecular Correlation.
Roy S; Manipadam MT; Balasubramanian P
Turk Patoloji Derg; 2022; 38(1):25-33. PubMed ID: 34514582
[TBL] [Abstract][Full Text] [Related]
28. Frequencies, Laboratory Features, and Granulocyte Activation in Chinese Patients with CALR-Mutated Myeloproliferative Neoplasms.
Guo H; Chen X; Tian R; Chang J; Li J; Tan Y; Xu Z; Ren F; Zhao J; Pan J; Zhang N; Wang X; He J; Yang W; Wang H
PLoS One; 2015; 10(9):e0138250. PubMed ID: 26375990
[TBL] [Abstract][Full Text] [Related]
29. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms.
Tefferi A; Thiele J; Vannucchi AM; Barbui T
Leukemia; 2014 Jul; 28(7):1407-13. PubMed ID: 24441292
[TBL] [Abstract][Full Text] [Related]
30. Detection of CALR Mutation in Clonal and Nonclonal Hematologic Diseases Using Fragment Analysis and Next-Generation Sequencing.
Gardner JA; Peterson JD; Turner SA; Soares BL; Lancor CR; Dos Santos LL; Kaur P; Ornstein DL; Tsongalis GJ; de Abreu FB
Am J Clin Pathol; 2016 Oct; 146(4):448-55. PubMed ID: 27686171
[TBL] [Abstract][Full Text] [Related]
31. CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms.
Belcic Mikic T; Pajic T; Sever M
Sci Rep; 2019 Dec; 9(1):19838. PubMed ID: 31882869
[TBL] [Abstract][Full Text] [Related]
32. Analysis of Common Driver Mutations in Philadelphia-Negative Myeloproliferative Neoplasms.
Alshemmari SH; Rajan R; Ameen R; Almazyad M
Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):483-488. PubMed ID: 33858806
[TBL] [Abstract][Full Text] [Related]
33. TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients.
Trifa AP; Bănescu C; Tevet M; Bojan A; Dima D; Urian L; Török-Vistai T; Popov VM; Zdrenghea M; Petrov L; Vasilache A; Murat M; Georgescu D; Popescu M; Pătrinoiu O; Balea M; Costache R; Coleș E; Șaguna C; Berbec N; Vlădăreanu AM; Mihăilă RG; Bumbea H; Cucuianu A; Popp RA
Br J Haematol; 2016 Jul; 174(2):218-26. PubMed ID: 27061303
[TBL] [Abstract][Full Text] [Related]
34. A rare CALR variant mutation and a review of CALR in essential thrombocythemia.
Diep R; Metjian A
J Thromb Thrombolysis; 2018 Apr; 45(3):457-462. PubMed ID: 29411299
[TBL] [Abstract][Full Text] [Related]
35. [Myeloproliferative neoplasms: revisions in the 2016 WHO criteria].
Hidaka T; Kamiunten A; Shimoda K
Rinsho Ketsueki; 2018; 59(8):1066-1071. PubMed ID: 30185707
[TBL] [Abstract][Full Text] [Related]
36. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
37. CALR mutation profile in Irish patients with myeloproliferative neoplasms.
Haslam K; Conneally E; Flynn CM; Cahill MR; Gilligan O; O'Shea D; Langabeer SE
Hematol Oncol Stem Cell Ther; 2016 Sep; 9(3):112-5. PubMed ID: 27352261
[TBL] [Abstract][Full Text] [Related]
38. A rare CALR variant mutation and efficient peginterferon alfa-2a response in a patient with essential thrombocythemia.
Ciftciler R; Balasar O
Cancer Genet; 2023 Jun; 274-275():51-53. PubMed ID: 36972657
[TBL] [Abstract][Full Text] [Related]
39. Calreticulin mutation profile in Indian patients with primary myelofibrosis.
Sazawal S; Singh N; Mahapatra M; Saxena R
Hematology; 2015 Dec; 20(10):567-70. PubMed ID: 25959795
[TBL] [Abstract][Full Text] [Related]
40. Capricious CALR mutated clones in myeloproliferative neoplasms.
Haslam K; Conneally E; Langabeer SE
Blood Cells Mol Dis; 2016 Mar; 57():110-1. PubMed ID: 26777583
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]